237
Participants
Start Date
May 31, 2014
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
MSB11022
Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
US-licensed Humira
Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
EU-approved Humira
Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
Fresenius Kabi SwissBioSim GmbH
INDUSTRY